Home

Patricia S Andrews

CIK 1445710 · Chief Commercial Officer · last filed 2026-06-03

Patricia S Andrews is a Chief Commercial Officer who has filed 21 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for ONCY, was dated Jun 3, 2026. Across all open-market trades the lifetime net is +$112.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $58.2K across reported positions. 8 SEC filings were submitted jointly with INCYTE CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$58.2K

Companies

4

Total Filings

21

Lifetime Open-Market Net

$112.3K

Filer Profile

Reported Address
4350 EXECUTIVE DRIVE, SUITE 325
SAN DIEGO, CA 92121
Related Filers
INCYTE CORP — 8 joint filings, latest 2012-01-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ONCY Director 78,128 $0.75 $58.2K $30.3K 2 2026-06-03
GERN Director — $1.35 — $0 1 2026-03-26
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director 586 $15.70 $9.2K $82.0K 11 2024-05-01
INCY Chief Commercial Officer — $121.47 — $0 7 2012-01-23

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-03 ONCY Grant (A) — $0 EDGAR
2026-03-26 GERN Grant (A) — $0 EDGAR
2026-02-13 ONCY Buy (P) +35,400 $30.3K EDGAR
2024-05-01 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2024-01-02 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) +5,191 $12.3K EDGAR
2023-10-03 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) +8,167 $12.3K EDGAR
2023-05-22 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2022-05-20 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2021-11-18 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Buy (P) +40,000 $82.0K EDGAR
2021-05-27 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) +5,250 $0 EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.